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WHAT THIS PAPER ADDS?
 Vacuum-assisted wound closure (VAC) treatment of infected bypass graft for lower limb ischaemia is an alternative minimally
invasive treatment to radical solutions such as resection or complete removal of bypasses followed by vascular reconstruction.a r t i c l e i n f o
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Objective: To assess the outcome of vacuum-assisted wound closure (VAC) therapy for infected bypass
grafts.
Methods: A retrospective 7-year review of patient records from 2004 to 2011 of all patients receiving
VAC therapy for infected bypass grafts.
Results: Thirty-seven patients with 42 wounds and 45 infected bypass (28 synthetic) grafts received VAC
treatment. Two serious bleeding episodes from the suture lines occurred. The median VAC therapy time
was 20 days. The proportion of patent bypass grafts was 91% (41/45) at a median time of 3.5 months from
the start of VAC therapy. Five patients with seven bypasses had persistent infection or re-infection, and
the total graft preservation rate was 76% (34/45). The median follow-up time was 15 months. The
presence of two infected bypass grafts in one groin wound was associated with an increased major
amputation rate (hazard ratio (HR) 7.4 [95% conﬁdence interval (CI) 2.0e27.5]), and synthetic graft
infection (HR 5.0 [95% CI 1.5e17.4]) and non-healed wound (HR 3.6 [95% CI 1.5e8.7]) were associated
with mortality.
Conclusion: VAC therapy of infected bypass grafts was able to induce effective wound healing without
compromising the early bypass function. Two infected synthetic bypasses in the wound were associated
with the highest risk of adverse outcome.
 2012 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.Deep peri-vascular postoperative wound infection in the groin
after arterial surgery is related to severe morbidity, long and costly
hospital stays, leg amputation and death.1 Patients with infection of
an exposed synthetic graft in the groin have often been treated by
removal or excision of the graft, with or without revascularisation
with an extra-anatomic bypass or in situ vein-bypass, with subse-
quent high risk of both leg amputation and death.2 Exposed and
infected grafts are sometimes treated with muscle ﬂap coverage
and antibiotics in an attempt to preserve the vascular reconstruc-
tion, but the re-infection rate has been reported to be as high as
66%.3 Vacuum-assisted wound closure (VAC) therapy of infected4640 338097.
).
ciety for Vascular Surgery. Publishgrafts in the groin alone has emerged as a simple and much less
invasive alternative to radical surgical solutions.4,5
Negative pressure wound therapy (NPWT), of which VAC
therapy is one particular system of treatment, has been reported to
have several beneﬁcial effects on healing wounds such as creating
a moist wound-healing environment, drainage of superﬂuous ﬂuid,
reduction of tissue oedema, cleansing deep wounds from bacteria,
accelerating the formation of vascularised granulation tissue and
faster approximation of wound edges.4e6
VAC therapy for deep wound infections following vascular
surgery has become routine in many hospitals worldwide. The
extension and depth of infection and the existence of synthetic
material in the wound are factors associated with morbidity,
amputation and mortality.4 Experience with VAC therapy for
infected bypasses in the lower limb, however, is limited.7 There areed by Elsevier Ltd. All rights reserved.
Figure 1. Patient who underwent radical extirpation for a sarcoma in the right thigh.
The femoral vein and superﬁcial femoral artery were resected. Arterial reconstruction
with a reversed saphena magna bypass graft, harvested from the contralateral leg, was
performed. The vascular anastomoses were located at the proximal superﬁcial femoral
artery and in the popliteal artery below knee. Postoperative wound necrosis and
infection developed. a) The forceps points at the saphena magna graft running visible
a few centimetres in the bottom of the wound. b) The VAC therapy applied. The
wound was completely healed after 76 days and duplex showed an unremarkable and
patent bypass graft.
S. Acosta, C. Monsen / European Journal of Vascular and Endovascular Surgery 44 (2012) 294e299 295two main concerns with this treatment modality for infected
bypasses. First, the amount of graft material in the wound is so
much larger compared to a patch or suture repair of an artery, and
there is always a risk that the infection spreads along the bypass
graft and the channel around the bypass. Second, the topical
negative pressure exerted on the bypass may in fact induce kinking
of the graft, resulting in a decreased ﬂow within the bypass and an
increased risk of bypass occlusion.
The aim of the present study was to assess early bypass graft
patency, and risk factors associated with wound healing, major
amputation and mortality after VAC therapy for infected bypass
grafts in the lower limb.
Material and Methods
Study population and setting
The Vascular Centre, Malmö-Lund, Malmö, Skåne University
Hospital is a tertiary referral centre for the southernmost part of
Sweden with a primary catchment population of approximately
800,000 inhabitants (Swedish Central Bureau of Statistics, www.
scb.se).
Patients undergoing groin incisions for any vascular procedure
were routinely given three prophylactic doses of the antibiotic
dicloxacillin (Ekvacillin), where the ﬁrst dose was administered at
induction of anaesthesia. Crosschecking for VAC-treated patients
was performed through our wound surveillance register that were
established and validated in 2007. According to this register, the
number of patients with peri-vascular groin infections (native
artery, and vein and synthetic prosthetic infections) during the last
5 years of this study (February 2007eJanuary 2012) was 66 or an
incidence of 1.7 per 100,000 person years. The number of patients
with peri-vascular infected bypass grafts was 24 during this period,
corresponding to an incidence of 0.6 per 100,000 person years. A
retrospective study of patient records from 1st of August 2004 until
31st of December 2011 of all patients receiving VAC therapy for
peri-vascular infected bypass grafts (Szilagyi grade III)1 after
vascular surgery was performed. Computed tomography (CT)
angiography was usually performed to evaluate the extent of the
bypass graft infection. Any duplex, CT angiography, ankleebrachial
index or clinical examination to assess the bypass function was
documented in the early follow-up, and local wound complications,
persistent or re-infection of the bypass, amputation and mortality
were checked from the day of wound debridement and revision to
the end of follow-up, 8th of March 2012.
Treatment policy of VAC therapy
Patients with deep wound infections underwent surgery for
wound revisionwith either regional or general anaesthesia. Wound
cultures adjacent to the bypass grafts were obtained. VAC therapy
was usually started the day after the revision at the surgical ward.
After administration of morphine intravenously, a polyurethane
sponge (KCI Medical, San Antonio, TX, USA) was applied with
a continuous topical negative pressure of 125 mmHg (standard
negative pressure inwound therapy recommended by KCI Medical)
(Fig. 1). Changes of dressings were performed after pain relief with
morphine intravenously at the surgical ward three times per week.
Visible graft material and native arteries were covered routinely
with a non-adhesive silicon-based dressing (Mepitel, Mölnlycke
Health Care AB, Göteborg, Sweden) to minimise any possible
trauma to the vascular anastomosis, which hypothetically could be
generated by the VAC therapy. The patients were treated in-
hospital, and usually with intravenous antibiotic therapy that
matched with the bacterial resistance pattern from the woundcultures, as long as any graft material or native artery was visible. In
the case of a negative initial wound culture, dicloxacillin or
piperacillinetazobaktam (after revised local guidelines) was
usually given intravenously until a later wound culture indicated
otherwise. As soon as the bypass graft was covered with granula-
tion tissue, in an otherwise ﬁt patient, VAC therapy sometimes
was carried out at homewith the mini-VAC portable device (VAC
Freedom), to achieve earlier hospital discharge and reduction in in-
hospital costs. Two secondary wound closures in the groin were
performed after 24 and 41 days of VAC therapy. The wound was
followed until full skin epithelialisation. Perioral antibiotic therapy
was usually continued for another 1e6 months after complete
wound healing.
Deﬁnitions
Early infection occurred within 3 months and late after 3
months from the responsible bypass surgical procedure.5 Hyper-
tension was deﬁned if the patient previously had been diagnosed
with hypertension or was taking anti-hypertensive medication.
Cerebrovascular disease was considered if there was a history of
Table 2
Predictors for complete wound healing, amputation and mortality during follow-up
after VAC therapy of infected bypass grafts.
Wounds
(%)
Wound
healed (%)
Major
amputation
(%)
Mortality
(%)
VAC therapy (all) 42 30/40 (75) 14 (33) 23 (55)
Women 11 (26) 8/10 (80) 3 (27) 6 (54)
Age  75 years 19 (45) 13/18 (72) 3 (16) 12 (63)
Co-morbidities
Ischaemic heart disease 18 (43) 11/17 (65) 8 (44) 12 (67)
Diabetes mellitus 12 (29) 9 (75) 6 (50) 8 (67)
Lower limb ischaemia 24 (57) 16/23 (70) 9 (38) 11 (46)
Cerebrovascular disease 7 (17) 7 (100) 1 (14) 3 (75)
Previous vascular surgery 29 (69) 20/28 (71) 12 (41) 15 (52)
Laboratory tests just prior to surgical revision
CRP ? 100mg/L 17/28 (61) 11/16 (69) 9 (53) 12 (71)
Renal insufﬁciency 22 (52) 14/21 (67) 7 (32) 13 (59)
Anaemia 34 (81) 22/32 (69) 11 (32) 20 (59)
Surgical factors
Multiple previous
groin incisions
26 (62) 18/25 (72) 11 (42) 13 (50)
Re-operation for bleeding 15 (36) 10/14 (71) 6 (40) 9 (60)
Synthetic graft infection 28 (67) 19/26 (73) 12 (43)* 20 (71)**
Two bypasses 9 (21) 4/8 (50) 6 (66)*** 6 (66)*
Wounds and microbiology
Staphylococcus aureus
at surgical revision
7 (17) 3 (43) 1 (14) 4 (57)
Intestinal ﬂora at
surgical revision
29 (69) 20/27 (74) 11 (38) 16 (55)
Critical limb ischaemia
with foot ulcer
13 (31) 11 (85) 5 (38) 5 (38)
Outcome
Wound not healed 10/40 (25) e 5 (50) 8 (80)***
Major amputation 14 (33) 9 (64) e 10 (71)
*p < 0.1, **p < 0.05, ***p < 0.01.
Table 3
Microbiology. Results of the wound cultures obtained at
primary surgical revision in the 42 wounds.
N
Skin ﬂora
Staphylococcus aureus 7
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attack (TIA). Ischaemic heart disease was considered if there was
a history of myocardial infarction, angina pectoris, coronary artery
bypass graft or percutaneous coronary angioplasty. Diabetes mel-
litus was noted if the patient had antidiabetic treatment with diet,
oral hypoglycaemic agents or insulin. Smoking included both
current and former tobacco smokers. Anaemia was deﬁned as
haemoglobin <134 g l1 in men and <117 g l1 in women.
Glomerular ﬁltration rate (GFR) was calculated by entering serum
creatinine level, age, gender and race into a formula provided by the
Modiﬁcation of Diet in Renal Disease Study Group.8 Renal insufﬁ-
ciency was present if GFR was <60 ml min1 in patients aged
50e65 years and <50 ml min1 in patients >65 years. Major
amputation was deﬁned as any amputation above the level of tar-
sometatarsal joint. Complete wound healing was deﬁned as full
skin epithelialisation and freedom from signs of local clinical
infection. The term EndoVAC refers to salvage of an arterial
reconstruction by reinforcing the infected vascular segment, that is,
sealing an extravasation from an arterial wall defect, pseudo-
aneurysm or ﬁstula, ﬁrst by an endovascular stent-graft pros-
thesis, followed by wound debridement and application of VAC
therapy.9
Statistical methods
Data management and statistical analysis were performed using
the SPSS for Windows, version 18.0 (SPSS Inc., Chicago, IL, USA).
Differences in proportions were analysed with the chi-square test
or Fisher’s exact test. Continuous variables were expressed in
median and range. Patient survival was analysed according to the
KaplaneMeier method with life table. Associations between factors
and mortality during follow-up were tested in a univariate Cox
regression model, and signiﬁcant associations were expressed in
terms of hazard ratios (HRs) with 95% conﬁdence interval (CI). P-
values <0.10 are denoted in Table 2 and p < 0.05 were considered
signiﬁcant.
Results
Patient characteristics
The median age of the 37 patients was 74 years (range 48e88
years). Co-morbidity factors such as hypertension and smoking
were both present in 37 (88%) out of the 42 VAC-treated wounds.
Detailed description of co-morbidities and wound characteristics
are shown in Table 1 and Table 2, left column. The microbiology
results from the initial wound cultures obtained at primary surgical
revision are shown in Table 3. Positive wound cultures were
obtained in 83% (35/42) of the wounds at surgical revision. PatientsTable 1
VAC therapy, wound healing and bypass graft function.
Wound treatment characteristics
Treated wounds/bypass grafts/patients 42/45/37
Abdominal wall/groin/thigh/calf 1/36/4/1
Synthetic grafts (%) 28 (67)
Duration of VAC therapy
Days; median (range) 20 (1e119)
Proportion of wounds treated outside hospital (%) 14 (33)
Results
Proportion of healed wounds (%) 30/40 (75)
Time to full skin epithelialisation (days); median (range) 75 (36e289); n ¼ 28
Patent bypass graft at ﬁrst follow-up (%) 41/45 (91)with two infected bypasses in the groin wound (n ¼ 9) were
infected in seven cases by Pseudomonas aeruginosa (n ¼ 3),
Enterococcus faecalis (n ¼ 1), Enterococcus faecium (n ¼ 1), Proteus
vulgaris (n ¼ 1), anaerobic bacteriae (n ¼ 1), Staphylococcus aureusStaphylococcus species 3
Streptococcus 1
Intestinal ﬂora
Enterococcus faecalis 9
Pseudomonas aeruginosa 7
Proteus mirabilis 7
Escherichia coli 4
Enterococcus faecium 4
Citrobacter freundii 2
Klebsiella pneumoniae 1
Proteus vulgaris 1
Corynebacterium species 1
Serratia marcescens 1
Anaerobic bacteriae 3
Faecal ﬂora 1
Candida albicans 1
Sum 53
S. Acosta, C. Monsen / European Journal of Vascular and Endovascular Surgery 44 (2012) 294e299 297(n ¼ 1) and Staphylococcus species (n ¼ 1), whereas two groin
wounds were negative in bacterial growth. Primary indications for
bypass surgery, which eventually led to deep wound infection,
were critical lower limb ischaemia (n ¼ 18; 43%), abdominal aortic
aneurysm (n ¼ 12; 29%), acute lower limb ischaemia (n ¼ 3; 7%),
claudication (n ¼ 3; 7%), chronic femoral artery pseudo-aneurysm
(n ¼ 2; 5%), femoral artery aneurysm (n ¼ 1; 2%), mycotic femoral
artery aneurysm (sepsis by S. aureus) (n¼ 1; 2%) and reconstruction
of arterial ﬂow after extirpation of sarcoma in the thigh (n ¼ 1; 2%).
The main clinical presentation of the deep wound infections
included the following: infected haematoma (n ¼ 15; 36%), skin
necrosis at surgical site (n ¼ 9; 21%), local bleeding (n ¼ 7; 17%),
abscesses (n ¼ 6; 14%), pseudo-aneurysm (n ¼ 2; 5%), ﬁstula to the
skin (n ¼ 2; 5%) and sepsis (n ¼ 1; 2%). Thirty-ﬁve (83%) wound
infections developed early and seven (17%) developed late.
The bypass operations
The bypass operations performed are shown in Table 4. Infected
synthetic bypass grafts were present in two-thirds (67%) of all 42
wounds. All 28 synthetic bypasses were made of polytetraﬂouro-
ethylene (PTFE, Gore-Tex). Two reconstructions of the femoral
artery were performedwith an interposition graft of an excised and
thrombendarterectomised superﬁcial femoral artery. One interpo-
sition bypass graft in the femoral artery was an exposed stent graft
sealing a large infected opening in the common femoral artery. Eight
patients had two infected bypasses: aorto-bifemoral þ femoro-
femoral interposition bypass (n ¼ 3), aorto-bifemoral þ femoro-
femoral bypass (n ¼ 1), aorto-bifemoral þ femoro-distal bypass
(n ¼ 1), aorto-bifemoral þ iliaco-femoral (obturatorius) bypass
(n ¼ 1), femoro-femoral þ femoro-popliteal bypass (n ¼ 1) and
femoro-femoral interposition þ femoro-popliteal below knee
bypass (n ¼ 1).
VAC therapy
VAC therapy was administered to 42 different infected wounds
and to 45 bypass grafts in 37 patients (Table 1). No information of
wound healing was possible to obtain in two patients, but 30 (75%)
wounds healed completely among the evaluable remaining 40
patients. The VAC therapies were administered to groinwounds in
86% (36/42) and to non-groin wounds in 14% (Table 1). Bleeding
episodes during VAC therapy occurred in three patients, two
bleedings were from the vascular anastomoses and one from the
granulation tissue. The two patients with serious bleeding episodes
had a femoral mycotic aneurysm presenting early due to S. aureus
sepsis repaired with an arterial interposition graft between the
common femoral artery to the profunda artery and a ﬁstula in the
groin presenting late after aorto-bifemoral and femoro-femoralTable 4
Graft anatomy and material among 37 patients with 45 bypasses undergoing VAC
therapy for infected bypass grafts in the lower limb.
By-pass graft anatomy Patients (%) Vein:Synthetic:Artery
Aorto-bifemoral bypass 3 (8) 0:3
Iliaco-femoral bypass 1 (3) 0:1
Femoro-femoral crossover bypass 7 (19) 1:6
Femoro-femoral interposition bypass 6 (16) 0:4:2
Femoro-popliteal above knee bypass 3 (8) 3:0
Femoro-popliteal below knee bypass 8 (22) 7:1
Femoro-distal bypass 1 (3) 1:0
Two bypass grafts 8 (22) 3:13
All 37 15:28:2interposition synthetic bypass procedures, respectively. The
suture lines from their vascular anastomoses were resected
without pursuing an alternative vascular reconstruction, and both
died in hospital due to sepsis and leg ischaemia, respectively. Four
sartorius muscle transposition ﬂaps in four groins in three patients
were performed as an additional wound treatment modality and
ﬁve stent graft (three Fluency, Bard Peripheral Vascular, Tempe,
AZ, USA) and two VIABAHN (Gore, Flagstaff, AZ, USA) treatment of
the common femoral artery via the endovascular route were per-
formed as reinforcement of the common femoral artery due to
formation of pseudo-aneurysm (n ¼ 3) and arterio-cutaneous
ﬁstula (n ¼ 2) as a part of an endoVAC procedure The median
VAC therapy time was 20 days (range 1e119) and the median in-
hospital stay was 30 days (6e115).Bypass graft patency after VAC therapy
The proportion of patent bypass grafts was 91% (41/45) at
a median time of 3.5 months from the surgical wound revision and
start of VAC therapy. Four bypasses were occluded: the two
patients referred to above with serious bleeding episodes had two
and one bypass graft, respectively. One bypass graft, with poor
outﬂow conditions for succeeding revascularisation, was found to
be occluded postoperative. The bypasses were controlled after
termination of VAC treatment, and usually after the wound had
healed completely, by duplex (n¼ 17; 41%), CT angiography (n¼ 11;
26%) and ankle-brachial index (n ¼ 14; 33%).Persistent infected or re-infected bypass grafts
After the VAC therapy period until end of follow-up, ﬁve
patients, with a total of seven bypasses, had serious persistent
infected or re-infected bypass grafts: two patients with two infec-
ted bypass grafts each in the groin underwent several reoperations
and ﬁnally graft resection without reconstruction, major amputa-
tions and death. Two patients had their infected femoro-femoral
crossover bypass removed and replaced with a saphena magna
vein bypass graft with uneventful courses. One patient had his
femoro-femoral bypass graft removed. Reconstruction was not
necessary since the patient already had undergone transtibial
amputation on the affected leg. The total graft preservation rate
after VAC therapy of infected bypass grafts was 76% (34/45).Factors associated with wound healing, amputation and mortality
The median follow-up time was 15 (range 0.2e70) months. The
complete wound healing rate was 75%, the major amputation rate
was 33% and the mortality rate was 55% at the end of follow-up
(Table 2). Five major amputations were performed as a conse-
quence of the groin infection and nine due to worsening of the
patients’ critical limb ischaemia. One minor amputation (toe
amputation) was performed. The presence of two infected bypass
grafts in one groin wound was associated with an increased major
amputation rate (p ¼ 0.003: HR 7.4 [95% CI 2.0e27.5]). There was
a trend (p ¼ 0.064) that synthetic graft infection was associated
with an increased major amputation rate. The 30-day and in-
hospital mortality rate were 5% (2/42) and 19% (8/42), respec-
tively, and the long-term mortality are shown in Fig. 2. Synthetic
graft infection (p¼ 0.011; HR 5.0 [95% CI 1.5e17.4]) and an unhealed
wound (p ¼ 0.005; HR 3.6 [1.5e8.7]) were factors associated with
mortality, and there was a trend that the presence of two infected
bypass grafts (p ¼ 0.068; HR 2.4 [95% CI 0.9e6.3]) was associated
with mortality in an uni-variate Cox regression analysis.
Figure 2. Long-term survival after VAC therapy for infected by-pass grafts. Numbers
below time axis denote patient wounds at risk at the respective time point. The tick
marks indicate censored data.
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The collected data from the present study represent one of the
largest experiences of infected bypass grafts treated with VAC
therapy. The high early bypass patency rate after VAC therapy of
deep peri-vascular wound infection suggests that VAC therapy
alone was capable of cleansing the wound, prevent infection along
the bypass and promote wound healing without compromising the
early bypass graft function in a decisive way during VAC therapy.
The bypass graft preservation rate was high, even at mid-term, and
high-risk procedures for excess morbidity and mortality such as
bypass removal and replacement were avoided. Indeed, two recent
encouraging reports5,10 have shown a low re-infection rate of grafts
after VAC therapy. On the other hand, one report has shown that,
aggressive staged surgical debridement, antiseptic and antibiotic
bed placement for ‘wound sterilisation’, sartorius muscle ﬂap, graft
excision or removal followed by in-situ vascular conduit replace-
ment with either rifampicin-PTFE or autologous vein bypass, can
achieve a high amputation-free survival rate in a dedicated vascular
centre.11
However, the present study has identiﬁed high-risk patients for
failure of graft preservation, major amputation and mortality, such
as those with two synthetic bypasses, converging in the infected
groin. First, the large amount of synthetic graft material with two
grafts creating a rugged area at the bottom of the wound makes the
wounds and the grafts difﬁcult to cleanse free from bacteria.
Second, failure of preserving one graft will affect the other, with
a high likelihood of a major amputation. Third, large suture lines
forming the vascular anastomosis are present with the inherent
increased risk of suture line breakage, disruption of the anasto-
mosis and bleeding during VAC therapy. Fourth, the presence of
two synthetic bypasses in one patient may be seen as a marker for
advanced atherosclerotic disease with an increased risk of
mortality during follow-up. Even if the risk of severe bleeding
complication from the suture line among all study patients was
low, it justiﬁes close surveillance of the bypass graft within hospital
as long as the graft is not incorporated with granulation tissue. If
synthetic bypass grafts are preserved and the wounds eventually
heal, these grafts should be considered to be bacterially contami-
nated for a long time onwards and long-term antibiotic therapy
should be mandatory in most cases to attempt to avoid the risk of
clinical re-infection. Close follow-up includes clinical examination,laboratory tests and CT angiography imaging of the affected area.
The study results suggest that patients with persistent infection or
re-infection of a femoro-femoral crossover synthetic bypass may be
better treated with removal of the graft and replacement with
a saphena magna vein crossover bypass graft.
Sartorius muscle ﬂap transpositions in the groin were occa-
sionally performed in the present study as an adjunctive procedure
after wound debridement and VAC therapy to accelerate wound
healing. Since prophylactic muscle ﬂap transposition procedures
have been recommended in high-risk patients with synthetic graft
material in the groin,12,13 it may be worthwhile to consider such
procedure in some high-risk patients with two synthetic bypass
grafts converging in the groin. Stent-graft placement in the
common femoral artery followed by wound debridement, endo-
VAC,8 were performed in rare occasions at the present highly
endovascular oriented unit. The rationale for this endovascular
approach, however, should be considered as experimental in view
of those other open surgical options that were available and may
only be used as a deﬁnitive bale-out procedure.
The majority of the wounds were infected with bacteria per-
taining to the intestinal ﬂora. S. aureus infection at the time point of
the initial surgical debridement operation was not found to be
associated with an unhealed wound, which may be attributed to
a statistical type II error. In a recent report, S. aureus infection was
associated with mortality,5 which partly may be attributed to its
more aggressive virulence properties14 compared to bacteria per-
taining to the intestinal ﬂora. In addition, patients presenting with
late infections after the index operation have been found to be at
a higher risk for subsequent re-infection after VAC therapy.5 Even
if these patients with clinical re-infection could be re-treated with
debridement and VAC therapy to achieve cure,5 this ﬁnding
implicates that proper treatment with surgical debridement and
VAC therapy should be initiated emergently as soon as diagnosis is
clear to stop further spreading of the infection along the bypass
graft, and minimise the risk of re-infection.
The overall major amputation rate may be considered high.
However, a large proportion of the patients had undergone
previous vascular surgery and suffered from critical limb ischaemia,
and most of the patients underwent major amputation due to
critical limb ischaemia, not as a consequence of the infected bypass.
The fact that the majority of the study patients had synthetic
infected bypass grafts has important clinical implications on
outcome, since placement of any synthetic graft material is a risk
factor for future surgical site infection or re-infection in the ﬁrst
place. When the synthetic graft infection is established, it is much
more challenging to treat than infected vein bypass grafts. Themid-
and long-term patency rates of infra-inguinal synthetic bypass
grafts are inferior to vein bypasses, contributing to a subsequent
higher amputation rate among thosewith synthetic bypass grafts.15
The rather high overall mortality rate might be explained by the
relatively high major amputation rate4 and the high burden of
illness among the study patients. For instance, the crude 1-year
mortality rate in patients with critical limb ischaemia without
a concomitant bypass graft infection has been reported to be 24% in
the same city16 as the present study population.
The limitations of the present study are attributed to its retro-
spective design and to incomplete duplex data on follow-up. The
inﬂuence of bodymass index on outcome datawas not addressed. A
multi-centre prospective study comparing outcome after VAC
therapy versus radical surgical solutions may be considered.
However, such a study might be very difﬁcult to conduct due to
expected recruiting problems and for ethical reasons, since bypass
excision/removal and extra-anatomic bypass/in-situ replacement is
considered as a major surgical procedure, whereas wound
debridement and VAC therapy is considered a minimally invasive
S. Acosta, C. Monsen / European Journal of Vascular and Endovascular Surgery 44 (2012) 294e299 299procedure. Establishing a register containing information on peri-
vascular wound infections would be helpful to ﬁnd out more
about the place of VAC therapy.
In conclusion, VAC therapy of infected bypass grafts seems to
be able to induce effective wound healing without compromising
the early bypass function. Two infected synthetic bypasses in the
wound were associated with the highest risk of adverse outcome.Conﬂict of Interest/Funding
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